Eco di Bergamo - 14 September 2024

There is potential for growth across all sectors in which the Group operates, with new investments in progress. According to CEO Giorgio Ferraris, the analysis of the first-half results for Fine Foods & Pharmaceuticals N.T.M. S.p.A. showed a promising outlook for sustained revenue and margin growth over the coming years.

The results for the first half of 2024 confirmed these positive prospects, showcasing a record EBITDA of €16 million (+27%) and margins of 13%.

Revenue for the half year reached €122.8 million, reaffirming Fine Foods' position as a leader in the contract manufacturing of nutraceuticals, pharmaceuticals, and cosmetics.

Details and full article HERE